The patient’s story
Here we report the case of a girl followed between the ages of 13 and 18 years with CD and aHUS. The patient was born after an uneventful twin pregnancy. Her twin brother has severe CD with complications necessitating repeated surgery for abdominal abscesses and fistulas. The first symptoms in our patient started in 2014 at the age of 13 with recurrent diarrhea, mucus in the stool, weight loss, and anemia. Initial laboratory data suggested CD (no pathogens in the stool culture, stool calprotectin, and anti-Saccharomyces cerevisiae antibodies (ASCA) IgG were elevated (> 900 microgram/g and 149 U/L, respectively)). The parents did not agree to performing an endoscopy at this stage.
In parallel, the patient had anemia, normal thrombocytes, proteinuria—reaching nephrotic range—and hematuria, while serum creatinine started to increase rapidly (223 micromole/L). Abdominal ultrasound showed enlarged hyperechogenic kidneys. Kidney biopsy was performed. Two days after the kidney biopsy, the complete clinical picture of aHUS developed with thrombocytopenia, hemolytic anemia, low haptoglobin levels, acute kidney impairment (serum creatinine 263 micromole/L), and high lactate dehydrogenase levels. Indeed, kidney histology confirmed the presence of thrombotic microangiopathy.
After Enterohemorrhagic E. coli (EHEC)–induced HUS diagnosis was ruled out, complement and genetic diagnostics were performed to establish the etiology of aHUS. Treatment of TMA was urgent due to rapidly decreasing kidney function (estimated glomerular filtration rate 23 mL/min/m2) and low thrombocyte levels before any knowledge of the patient’s genetic background. Transfusions of fresh frozen plasma (FFP, 18 times), therapeutic plasma exchange sessions (4 times), and intravenous steroid shots (250 mg each, 3 times) were performed to eliminate eventual anti-factor H antibodies.
Hemolysis was stopped before the initial treatment, and hematological response was reached; however, proteinuria, hematuria persisted, and serum creatinine remained high. To avoid chronic kidney failure, complement-blocking therapy was urgent. Six weeks after the diagnosis of aHUS, complement blockade with eculizumab (ECU) became available and was started with an initial dose of 900 mg (for her weight of 38 kg).
Complement measurements (all pathway activities, complement activation products, and ADAMTS13 (a distintegrin and metalloprotease with thrombospondin-1-like domains, member 13)) were performed. Total classical (CH50, sheep red blood cell hemolytic titration, reference range: 48–103 CH50/mL) and alternative pathway (ALT, Wieslab Comp AP330 kit, 70-125%, Euro Diagnostica, Malmö, Sweden) activities and free serum ECU (in-house enzyme-linked immunosorbent assay from 2016 onward) levels were performed systematically directly before starting ECU infusion every 2 weeks. Fully suppressed CH50 and ALT activities were defined as an activity below 10%. Serum ECU concentrations of 50–100 microgram/mL were considered to achieve complete complement blockade [7].
Signs of effective complement blockade were detected without delay. Classical and alternative pathway activities were depleted. Low C3 and C4 levels, as signs of severe complement consumption, normalized (to 1.1 mg/L and 0.56 mg/L, respectively). Lower ADAMTS13 activity values (54–77%), as a sign of secondary endothelial damage [8], returned to normal (99–111%). ECU treatment was continued and a satisfying nephrological response was reached; creatinine returned to normal, and proteinuria decreased gradually to the normal range. Other, supportive aHUS therapies (PE, FFP) were stopped.
A thorough genetic study of the complement system was performed and revealed the presence of a previously undescribed “likely pathogenic” factor I variant (R339L). In silico prediction of variant pathogenicity was assessed, showing that the serine protease domain of human complement factor I was affected. In addition, CFH tgtgt and MCP ggaac aHUS risk haplotypes were detected. The twin brother carries the same factor I variant (R339L), the CFH tgtgt and MCP ggaac risk haplotypes. The mother bears the same CFI mutation and the MCP ggaac risk haplotype and is heterozygous for the CFH tgtgt risk haplotype. Family history was negative for aHUS despite this genetic background.
Emerging problems
ECU therapy was started in 2014 and was continued systematically every 2 weeks during the entire study period. Maintenance ECU was initially 900 mg (every 2 weeks). Unexpectedly, a remarkable intra-patient variation of complement inhibition was observed. In spite of continuous complement-blocking therapy, peaks of complement pathway activities (CH50, ALT) were observed, the blockade was incomplete, and a strong association with the recurrence of bowel symptoms was found. In response, first the ECU dose was increased (to 1200 mg every 2 weeks, as the patient’s weight meanwhile had increased to 42 kg) assuming that the patient needed a higher dose due to weight gain. However, complement blockade was reduced even at higher doses during CD relapse. An ileum biopsy performed in April 2016 showed the typical histological picture of CD. Conventional treatment for CD (steroids, local steroids, and azathioprine) was started, with a rapid remission of CD. Non-compliance with conventional therapy resulted in CD recurrence in October 2017, coupled with the development of a perianal fistula. Biological treatment with adalimumab, a fully human, high-affinity, recombinant anti-tumor necrosis factor alpha monoclonal antibody [9], was introduced, which resulted in the remission of CD.
Figure 1 shows the variation of complement activity with time (on day 14 after administering the prescribed dose and before the next dose) as a function of the course of intestinal disease. While CD was in remission, complete complement blockade was achieved, and CH50 and ALT pathway activities were below 10%. However, during CD recurrence, the efficacy of complement blockade decreased dramatically.
To determine the cause of this intra-patient variability, other potential factors were analyzed. Proteinuria had not been detected since 2015, and intestinal bleeding was not significant. Free ECU serum levels were analyzed shortly before the next ECU dose from 2016 onward. Serum levels decreased to subtherapeutic concentrations (< 8–10 microgram/mL) despite regular dosing. As shown in Fig. 1, with stable doses of ECU (1200 mg every 2 weeks), therapeutic levels (> 50 microgram/mL) were reached shortly after the start of adalimumab therapy. Despite low ECU levels and incomplete complement inhibition, no clinical or hematological signs of TMA activity were observed during the recurrence of CD. The patient’s weight was stable (between 50 and 55 kg) from the age of 16. The patient remained in hematologic and renal remission throughout the study period. C3 (median (1.2 mg/L (IQR 0.99–1.37)), C4 (0.4 mg/L (IQR 0.28–0.45)), and ADAMTS13 activity (median 101% (IQR 91–115%)) values were within the normal range from the start of ECU therapy.